Dan Sheehan
Analyst · Barclays. Please go ahead
Thanks, Tom, and good morning, everyone. I am pleased with the continued progress made during the quarter with strong earnings and capital ratios in our U.S. mortgage insurance business and results from our LTC multi-year rate action plan. At our holding company, we continue to deleverage including fully retiring the February debate maturity, prepaying a material portion of the AXA obligation, and reducing the amount outstanding on our September '21 maturities. We also ended the quarter with more than $750 million in holding company cash. We reported net income available to Genworth shareholders in the quarter of $187 million and adjusted operating income of $168 million. Included in net income for the quarter was $33 million in mostly mark-to-market gains and a $30 million benefit in discontinued operations primarily related to tax items on prior divestures. These items were partially offset by $21 million in severance cost related to our previously announced restructuring. The U.S. mortgage and housing market continues to perform very well with increasing home prices, a large origination market, and continuation of decrease in new delinquencies from their earlier peak. We view the stimulus initiatives, forbearance extensions, and the strong home price appreciation as positives for delinquency in development, and ultimate claims. Overall financial results for U.S. MI in the first quarter were once again driven by growth of our insurance in-force and lower levels of new delinquencies compared to the prior quarter. For the quarter, U.S. MI reported adjusted operating income of $126 million, and the loss ratio of 22%. New insurance written in U.S. MI was $24.9 billion in the quarter, up 39% versus the prior-year, primarily driven by higher mortgage originations and a larger private mortgage insurance market. Although most of our peers have not reported, we estimate our market share will reflect a modest sequential overall market share gain in the quarter. The low interest rate environment and resulting high levels of refinance activity continue to drive low persistency levels in our insurance portfolio. Lower persistency has impacted our business in several ways, including partially offsetting portfolio growth from NIW increasing single premium cancellations, accelerating the amortization of our existing reinsurance transactions, and shifting our portfolio concentration to newer book years. Single premium cancellations continue to remain elevated, benefiting premiums during the quarter by $26 million, which was down slightly from the $30 million in each of the third and fourth quarter last year. In addition, we ceded $16 million of premiums related to our credit risk transfer program in the quarter, which is higher by $1 million sequentially given the expansion of our credit risk transfer program, while new delinquencies of approximately 10,000 during the first quarter was still elevated versus pre-COVID levels, they were down 16% sequentially, with approximately 54% reported in forbearance plans. New delinquencies resulted in $44 million in loss expense in the quarter and our expected ultimate claim rate was approximately 8%. Cures of approximately 13,500 were down 19% sequentially, and continue to outpace new delinquencies. We ended the quarter with approximately 41,000 total delinquencies or delinquency rate of 4.5%. In total, approximately 70% of our delinquencies are in forbearance, and 90% have mark-to-market loan to values reflecting at least 10% borrower equity using December 2020 home prices. Our servicer reported forbearance trends continue to climb from peak levels in May 2020, and ended the first quarter with 4.9% or approximately 45,000 of our active policies reported in a forbearance plan, with 36% of those in forbearance, still reported as current. During the quarter, we increased our reserves for pre-COVID delinquencies by $10 million pretax. The reserve increase primarily reflects our expectation that these pre-COVID delinquencies will have a modestly higher claim rate than the company's prior best estimate, given the slower emergence of cures. In U.S. Life, the segment reported adjusted operating income of $62 million in the quarter compared to adjusted operating income of $129 million in the prior-quarter, and an adjusted operating loss of $70 million in the prior-year. Our U.S. Life businesses continue to experience elevated mortality that we believe is attributable in part to the COVID-19 pandemic. In long-term care, adjusted operating income was $95 million in the first quarter, compared to $129 million in the prior quarter and $1 million in the prior-year. Underlying results continue to reflect the cumulative benefits of our approximately eight-year track record of achieving significant LTC premium rate increases and benefit reductions. Claim terminations were higher in the first quarter versus the prior quarter and prior-year, we did not require death certificates for LTC terminations, but we assume that the elevated terminations were primarily driven by COVID-19. We believe that the elevated claim terminations this quarter and during the pandemic are temporary and have primarily impacted our most vulnerable claimants. We increased our claim reserves by $67 million pretax this quarter, continuing our view that our remaining claim population is less likely to terminate than the pre-pandemic average. In addition, new claim submissions continue to remain lower than expected, driving additional favorable IBNR development of $29 million pretax during the quarter. We currently believe that the pandemic driven decrease in incidents is temporary, and that our incidents experience will ultimately resemble previous trends. Shifting to in-force rate actions for LTC, the overall benefits from in-force rate actions have remained strong. For the quarter, Genworth received approvals, impacting approximately $396 million of premiums with a weighted average approval rate of 40% on a cumulative net present value basis from 2012 through 1Q '21, we've achieved approximately $15.2 billion of approved LTC premium rate increases and benefit reductions. We expect strong approvals throughout 2021 based on our filings during 2020. Turning to Life Insurance, overall mortality for the quarter continued to be elevated versus historical trends and was up versus the prior quarter and year. The first quarter included an estimate of approximately $35 million after tax and COVID-19 related claims based upon death certificates received to date. Even absent, these COVID-19 related claims, mortality remained elevated during the quarter, consistent with trends observed throughout the pandemic. Term life insurance products continue to be negatively impacted by short lapses, although this impact will continue to lessen through 2021. Total term life insurance stack amortization reduced earnings by $13 million after-tax versus $18 million after tax in the prior quarter and $27 million in the prior year. In fixed annuities, adjusted operating earnings of $30 million for the quarter was higher compared to the prior quarter and prior year driven by higher mortality and favorable equity markets and interest rates. In the runoff segment, our adjusted operating income was $12 million for the first quarter, down slightly versus the prior quarter, and up from last year due to improve the equity markets and interest rates. Rounding out the results corporate and others adjusted operating loss was $32 million and was down from last quarter in the prior year, primarily driven by lower corporate expenses and interest expense. Our de-leveraging efforts this quarter and moving forward are projected to decrease the losses in the segment in the quarters ahead. Turning to capital levels and USMI, we finished the quarter with an estimated PMIER sufficiency ratio of 159% or approximately $1.8 billion above published requirements. The improvement in our PMIER sufficiency versus the prior quarter was driven primarily by the completion of an insurance link no transaction on seasoned loans, which provided approximately $500 million of PMIERs credit at the quarter end. Subsequent to the quarter, we also executed an ILN on a portion of our 2020 books, which will provide approximately $300 million of PMIERs credit. If we gave effect of this transaction in the first quarter of 2021, our PMIERs sufficiency would have increased to 176% or approximately $2.1 billion above the published PMIERs environments. These transactions, which are part of our credit risk transfer program, are assigned to provide cost-effective capital relief and reduce loss volatility. We expect capital in Genworth Life Insurance Company or GLIC as a percentage of company action level RBC to be approximately 255%, up from 229% at year-end. U.S. life statutory income in the first quarter benefited from earnings and LTC from trends in termination and incidents as well as from in-force rate actions. As we've discussed in the past, we have no plans to infuse additional capital into or extract capital from our U.S. life insurance businesses. Going forward, the U.S. life insurance businesses will continue to rely on the consolidated statutory capital of approximately $2.3 billion as of the end of the first quarter, significant claim and ALR reserves, prudent management of in-force blocks, and actuarially justified rate actions to satisfy obligations to our policy holders. For holding company cash, we ended the quarter in a very strong cash position, the $757 million in cash and liquid assets, or approximately $495 million above our targeted cash buffer. This excludes approximately $284 million in cash held at USMIs intermediate holding company, Genworth Mortgage Holdings, Inc. GMHI, paid 16 of the investor presentation provides the quarterly activity including proceeds of $370 million from the sale of our interest in the Australia business and intercompany tax payments of $87 million reflecting strong underlying taxable income from our U.S. insurance subsidiaries. The $729 million of debt reduction during the quarter includes the February debt maturity of $338 million, acts of prepayments of $245 million triggered by the Australia business sale and open market repurchases of $146 million of the September 21 maturities. As we look forward in 2021 with our cash on hand and the plan sale of a portion of our interest in USMI, our current plans include prepaying the remaining AXA obligation of approximately $345 million, and the current outstanding balance, on the September 21 maturities, of $513 million. This will leave $400 million due in both August 23 and February 24 to be covered by cash on hand and the resumption of U.S. MI dividends. After the February 2024 maturity, our remaining holding company debt is $300 million, due in 2034, and $600 million due in 2066. As Tom indicated, given the strength of our expected cash position and the meaningful benefits provided by tax consolidation, we have no further plans to sell U.S. MI beyond what is currently contemplated. In closing, we've taken numerous steps to improve the liquidity and financial flexibility of our holding company and the position of our businesses. We're pleased with our financial progress and remain focused on providing value to all key stakeholders. One final note, as Tim noted earlier, due to applicable securities law restrictions, our comments regarding the status of preparations or other matters related to a planned offering of a portion of our interest in our U.S. mortgage business will be limited to our prepared remarks. With that, we will now open the line for questions.